Precision Biosciences INC 10-Q quarterly reports

Precision BioSciences reported its Q2 2026 financial results, highlighting progress in its gene editing programs PBGENE-HBV and PBGENE-DMD, while continuing to incur net losses.

Precision BioSciences Inc. reported its first quarter 2026 financial results, highlighting significant revenue growth driven by collaboration agreements and continued investment in its lead gene editing programs.

Precision BioSciences reported a significant net loss in Q3 2025, driven by reduced collaboration revenue, while advancing its lead gene editing programs and extending its cash runway into late 2027.

Precision BioSciences reported a significant net loss in Q2 2025 due to reduced collaboration revenue, while highlighting positive clinical and preclinical data for its gene editing programs and extending its cash runway.

Precision BioSciences announces its Q1 2025 financial results, emphasizing advancements in its in vivo gene editing therapies, particularly PBGENE-HBV and PBGENE-DMD.

Precision BioSciences reports a net loss of $16.4 million for Q3 2024, while highlighting progress in its in vivo gene editing programs and strategic collaborations.

Precision BioSciences reports a significant increase in revenue for the second quarter of 2024, primarily driven by collaboration agreements and strategic transactions.

Precision BioSciences reports a significant increase in revenue for the first quarter of 2024, driven by new licensing agreements and continued progress in its in vivo gene editing programs.